Frank Scott
Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 28 | 2026 | 349 | 8.670 |
Why?
| | Crohn Disease | 16 | 2025 | 249 | 5.640 |
Why?
| | Gastrointestinal Agents | 7 | 2025 | 65 | 3.440 |
Why?
| | Gastroenterology | 7 | 2025 | 178 | 2.180 |
Why?
| | Colitis, Ulcerative | 9 | 2025 | 136 | 2.130 |
Why?
| | Infliximab | 10 | 2022 | 111 | 1.570 |
Why?
| | Intestinal Obstruction | 3 | 2021 | 51 | 1.500 |
Why?
| | Tissue Adhesions | 3 | 2021 | 32 | 1.270 |
Why?
| | Immunosuppressive Agents | 6 | 2020 | 863 | 1.270 |
Why?
| | Adrenal Cortex Hormones | 4 | 2022 | 491 | 1.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2025 | 821 | 1.130 |
Why?
| | Tumor Necrosis Factor-alpha | 10 | 2023 | 1243 | 1.120 |
Why?
| | Algorithms | 7 | 2026 | 1701 | 1.040 |
Why?
| | Patient Acceptance of Health Care | 5 | 2026 | 849 | 0.980 |
Why?
| | Intestine, Small | 2 | 2021 | 155 | 0.980 |
Why?
| | Biological Products | 4 | 2026 | 222 | 0.950 |
Why?
| | Ustekinumab | 2 | 2025 | 16 | 0.910 |
Why?
| | JC Virus | 2 | 2015 | 23 | 0.890 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2015 | 37 | 0.870 |
Why?
| | Drug Monitoring | 1 | 2026 | 209 | 0.870 |
Why?
| | Azathioprine | 5 | 2021 | 49 | 0.820 |
Why?
| | Humans | 91 | 2026 | 137601 | 0.810 |
Why?
| | Bone Diseases, Metabolic | 1 | 2023 | 64 | 0.800 |
Why?
| | Abdomen | 2 | 2021 | 128 | 0.770 |
Why?
| | Esophageal Neoplasms | 6 | 2022 | 319 | 0.760 |
Why?
| | Abdominal Abscess | 1 | 2022 | 25 | 0.760 |
Why?
| | Postoperative Complications | 3 | 2021 | 2665 | 0.710 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2023 | 134 | 0.700 |
Why?
| | Retrospective Studies | 27 | 2026 | 15720 | 0.690 |
Why?
| | Severity of Illness Index | 9 | 2025 | 2840 | 0.680 |
Why?
| | Anti-Bacterial Agents | 5 | 2018 | 1799 | 0.680 |
Why?
| | Splints | 1 | 2020 | 14 | 0.670 |
Why?
| | Capsule Endoscopy | 1 | 2020 | 18 | 0.660 |
Why?
| | Antibodies, Viral | 2 | 2015 | 648 | 0.660 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2020 | 24 | 0.650 |
Why?
| | Barrett Esophagus | 4 | 2023 | 150 | 0.640 |
Why?
| | Radius Fractures | 1 | 2020 | 60 | 0.630 |
Why?
| | Biomedical Research | 2 | 2019 | 696 | 0.620 |
Why?
| | Quality-Adjusted Life Years | 5 | 2021 | 108 | 0.600 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2021 | 448 | 0.590 |
Why?
| | Spondylarthritis | 3 | 2025 | 50 | 0.590 |
Why?
| | Colonoscopy | 7 | 2024 | 249 | 0.590 |
Why?
| | Adult | 37 | 2026 | 37910 | 0.580 |
Why?
| | Hospitalization | 4 | 2026 | 2197 | 0.580 |
Why?
| | Drug Utilization | 1 | 2019 | 168 | 0.570 |
Why?
| | Intestinal Fistula | 1 | 2018 | 18 | 0.570 |
Why?
| | Colonic Diseases | 1 | 2018 | 34 | 0.560 |
Why?
| | Surgical Procedures, Operative | 1 | 2021 | 260 | 0.560 |
Why?
| | Health Resources | 1 | 2019 | 124 | 0.560 |
Why?
| | Pericardium | 1 | 2018 | 55 | 0.560 |
Why?
| | Tuberculin Test | 1 | 2017 | 36 | 0.560 |
Why?
| | Cost-Benefit Analysis | 5 | 2021 | 592 | 0.550 |
Why?
| | Biological Factors | 2 | 2023 | 39 | 0.540 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2018 | 98 | 0.530 |
Why?
| | Models, Statistical | 2 | 2019 | 666 | 0.530 |
Why?
| | Male | 48 | 2026 | 67690 | 0.530 |
Why?
| | Middle Aged | 37 | 2026 | 33441 | 0.520 |
Why?
| | Latent Tuberculosis | 1 | 2017 | 68 | 0.520 |
Why?
| | Time-to-Treatment | 2 | 2019 | 204 | 0.520 |
Why?
| | Mass Screening | 4 | 2021 | 1279 | 0.520 |
Why?
| | Colorectal Neoplasms | 6 | 2024 | 801 | 0.500 |
Why?
| | Treatment Outcome | 14 | 2025 | 10813 | 0.490 |
Why?
| | Remission Induction | 3 | 2025 | 290 | 0.490 |
Why?
| | Antibodies, Monoclonal | 4 | 2021 | 1425 | 0.480 |
Why?
| | Natalizumab | 1 | 2015 | 40 | 0.460 |
Why?
| | Radius | 1 | 2015 | 50 | 0.460 |
Why?
| | Heart Diseases | 1 | 2018 | 328 | 0.450 |
Why?
| | Fracture Fixation | 1 | 2015 | 79 | 0.440 |
Why?
| | Mycobacterium tuberculosis | 1 | 2017 | 317 | 0.440 |
Why?
| | Female | 44 | 2026 | 73359 | 0.430 |
Why?
| | Age Factors | 5 | 2025 | 3253 | 0.430 |
Why?
| | Models, Theoretical | 1 | 2018 | 578 | 0.430 |
Why?
| | Practice Patterns, Physicians' | 3 | 2024 | 1299 | 0.420 |
Why?
| | Aged | 27 | 2024 | 23938 | 0.410 |
Why?
| | Leukocyte L1 Antigen Complex | 2 | 2026 | 31 | 0.410 |
Why?
| | Markov Chains | 3 | 2020 | 125 | 0.400 |
Why?
| | Lymphoma | 1 | 2014 | 210 | 0.390 |
Why?
| | Risk Factors | 17 | 2025 | 10319 | 0.390 |
Why?
| | Drug Therapy, Combination | 4 | 2024 | 1036 | 0.380 |
Why?
| | Adalimumab | 3 | 2021 | 53 | 0.370 |
Why?
| | Communicable Diseases | 1 | 2014 | 161 | 0.370 |
Why?
| | Patient Discharge | 2 | 2023 | 901 | 0.360 |
Why?
| | Feces | 3 | 2026 | 480 | 0.360 |
Why?
| | United Kingdom | 5 | 2021 | 317 | 0.360 |
Why?
| | Gastroenterologists | 2 | 2022 | 18 | 0.350 |
Why?
| | Professional Competence | 1 | 2012 | 97 | 0.350 |
Why?
| | Disease Management | 3 | 2021 | 619 | 0.350 |
Why?
| | Cohort Studies | 10 | 2025 | 5691 | 0.340 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 645 | 0.330 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 353 | 0.330 |
Why?
| | Spondylitis, Ankylosing | 2 | 2021 | 47 | 0.330 |
Why?
| | Research Design | 2 | 2019 | 1110 | 0.330 |
Why?
| | Fractures, Bone | 1 | 2015 | 393 | 0.330 |
Why?
| | Gastroesophageal Reflux | 2 | 2023 | 239 | 0.320 |
Why?
| | Research Personnel | 1 | 2012 | 184 | 0.320 |
Why?
| | Colonic Polyps | 2 | 2024 | 88 | 0.320 |
Why?
| | Adenoma | 3 | 2024 | 225 | 0.320 |
Why?
| | United States | 17 | 2025 | 14925 | 0.310 |
Why?
| | Proportional Hazards Models | 5 | 2021 | 1272 | 0.310 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2017 | 261 | 0.300 |
Why?
| | Pediatric Obesity | 1 | 2016 | 591 | 0.300 |
Why?
| | Societies, Medical | 4 | 2025 | 818 | 0.290 |
Why?
| | Janus Kinase Inhibitors | 2 | 2025 | 27 | 0.290 |
Why?
| | Skin Neoplasms | 1 | 2016 | 849 | 0.290 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2025 | 1468 | 0.280 |
Why?
| | Quality of Life | 2 | 2021 | 2942 | 0.280 |
Why?
| | Electronic Health Records | 6 | 2022 | 1073 | 0.280 |
Why?
| | Incidence | 8 | 2021 | 2805 | 0.280 |
Why?
| | Databases, Factual | 7 | 2018 | 1382 | 0.260 |
Why?
| | Mortality | 2 | 2020 | 354 | 0.260 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2017 | 1038 | 0.250 |
Why?
| | Maintenance Chemotherapy | 1 | 2025 | 36 | 0.240 |
Why?
| | Radiography | 2 | 2020 | 844 | 0.240 |
Why?
| | Referral and Consultation | 2 | 2023 | 794 | 0.240 |
Why?
| | Consensus | 2 | 2025 | 673 | 0.240 |
Why?
| | Population Surveillance | 2 | 2021 | 479 | 0.230 |
Why?
| | Induction Chemotherapy | 1 | 2025 | 77 | 0.230 |
Why?
| | Antifungal Agents | 2 | 2016 | 140 | 0.230 |
Why?
| | Aged, 80 and over | 10 | 2020 | 7609 | 0.230 |
Why?
| | Case-Control Studies | 8 | 2021 | 3550 | 0.220 |
Why?
| | Evidence-Based Medicine | 2 | 2025 | 739 | 0.220 |
Why?
| | Recurrence | 5 | 2021 | 1073 | 0.220 |
Why?
| | Esophageal Stenosis | 2 | 2014 | 55 | 0.210 |
Why?
| | Delivery of Health Care | 2 | 2021 | 952 | 0.210 |
Why?
| | Surveys and Questionnaires | 8 | 2025 | 5835 | 0.210 |
Why?
| | Adenocarcinoma | 2 | 2021 | 881 | 0.210 |
Why?
| | Gastrointestinal Microbiome | 2 | 2022 | 699 | 0.210 |
Why?
| | Obesity | 1 | 2017 | 2985 | 0.210 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2024 | 90 | 0.200 |
Why?
| | C-Reactive Protein | 1 | 2026 | 411 | 0.200 |
Why?
| | Colectomy | 2 | 2021 | 100 | 0.200 |
Why?
| | Esophagitis, Peptic | 1 | 2023 | 15 | 0.200 |
Why?
| | Protective Factors | 2 | 2021 | 95 | 0.200 |
Why?
| | Models, Economic | 2 | 2020 | 59 | 0.200 |
Why?
| | Glucocorticoids | 2 | 2018 | 528 | 0.200 |
Why?
| | Logistic Models | 6 | 2018 | 2076 | 0.200 |
Why?
| | Absorptiometry, Photon | 1 | 2023 | 262 | 0.200 |
Why?
| | Prognosis | 4 | 2019 | 3966 | 0.190 |
Why?
| | Comparative Effectiveness Research | 2 | 2024 | 153 | 0.190 |
Why?
| | Cellulitis | 1 | 2022 | 55 | 0.190 |
Why?
| | Medical Marijuana | 1 | 2024 | 121 | 0.190 |
Why?
| | Odds Ratio | 4 | 2018 | 1074 | 0.180 |
Why?
| | Insurance, Health | 1 | 2024 | 288 | 0.180 |
Why?
| | Amputation, Traumatic | 1 | 2021 | 20 | 0.180 |
Why?
| | Necrosis | 1 | 2022 | 247 | 0.180 |
Why?
| | Finger Injuries | 1 | 2021 | 25 | 0.180 |
Why?
| | Rectal Fistula | 1 | 2021 | 27 | 0.170 |
Why?
| | Pancreatic Neoplasms | 2 | 2021 | 853 | 0.170 |
Why?
| | Vascular Surgical Procedures | 2 | 2021 | 310 | 0.170 |
Why?
| | Aftercare | 1 | 2023 | 207 | 0.170 |
Why?
| | Liver Transplantation | 2 | 2021 | 843 | 0.170 |
Why?
| | Prevalence | 4 | 2025 | 2735 | 0.170 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5121 | 0.170 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2021 | 64 | 0.170 |
Why?
| | Esophagoscopy | 2 | 2022 | 210 | 0.170 |
Why?
| | Artificial Intelligence | 1 | 2024 | 291 | 0.170 |
Why?
| | Cystectomy | 2 | 2017 | 41 | 0.170 |
Why?
| | Utilization Review | 1 | 2020 | 40 | 0.170 |
Why?
| | Sugars | 1 | 2020 | 39 | 0.160 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1541 | 0.160 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 104 | 0.160 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 36 | 0.160 |
Why?
| | Bone Density | 1 | 2023 | 489 | 0.160 |
Why?
| | Bone Plates | 1 | 2020 | 77 | 0.160 |
Why?
| | Carcinoma | 1 | 2021 | 230 | 0.160 |
Why?
| | Urologic Surgical Procedures | 1 | 2021 | 112 | 0.160 |
Why?
| | Tryptophan | 1 | 2021 | 183 | 0.160 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 326 | 0.160 |
Why?
| | Diabetes Mellitus | 2 | 2021 | 1052 | 0.160 |
Why?
| | Metagenomics | 1 | 2021 | 177 | 0.150 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1941 | 0.150 |
Why?
| | Hospitals | 2 | 2021 | 691 | 0.150 |
Why?
| | Deglutition Disorders | 1 | 2021 | 148 | 0.150 |
Why?
| | Hospitals, Veterans | 1 | 2020 | 255 | 0.150 |
Why?
| | Obesity, Morbid | 1 | 2023 | 263 | 0.150 |
Why?
| | Child | 6 | 2023 | 21833 | 0.150 |
Why?
| | Metabolomics | 2 | 2022 | 686 | 0.150 |
Why?
| | Chronic Disease | 2 | 2022 | 1788 | 0.150 |
Why?
| | Diverticulum | 1 | 2018 | 12 | 0.150 |
Why?
| | Job Satisfaction | 1 | 2021 | 215 | 0.150 |
Why?
| | Hematemesis | 1 | 2018 | 3 | 0.140 |
Why?
| | Health Care Costs | 1 | 2021 | 414 | 0.140 |
Why?
| | Infant | 5 | 2020 | 9539 | 0.140 |
Why?
| | Symptom Assessment | 2 | 2017 | 129 | 0.140 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 265 | 0.140 |
Why?
| | Fracture Fixation, Internal | 1 | 2020 | 192 | 0.140 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 407 | 0.140 |
Why?
| | Intestines | 1 | 2021 | 354 | 0.140 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2017 | 25 | 0.140 |
Why?
| | Clostridium Infections | 1 | 2018 | 72 | 0.130 |
Why?
| | Fatal Outcome | 1 | 2018 | 309 | 0.130 |
Why?
| | Arthritis, Rheumatoid | 2 | 2016 | 1156 | 0.130 |
Why?
| | Ambulatory Care | 1 | 2021 | 571 | 0.130 |
Why?
| | Risk Assessment | 3 | 2016 | 3438 | 0.130 |
Why?
| | Quality of Health Care | 1 | 2021 | 649 | 0.130 |
Why?
| | Cystadenoma, Mucinous | 1 | 2016 | 10 | 0.130 |
Why?
| | Continuity of Patient Care | 1 | 2019 | 282 | 0.130 |
Why?
| | Budesonide | 1 | 2016 | 56 | 0.130 |
Why?
| | Itraconazole | 1 | 2016 | 8 | 0.120 |
Why?
| | Pharmacoepidemiology | 1 | 2015 | 20 | 0.120 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2016 | 58 | 0.120 |
Why?
| | Endoscopy, Gastrointestinal | 3 | 2023 | 229 | 0.120 |
Why?
| | Pancreatic Diseases | 1 | 2016 | 66 | 0.120 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1044 | 0.120 |
Why?
| | Guideline Adherence | 1 | 2020 | 551 | 0.120 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 5507 | 0.120 |
Why?
| | Cysts | 1 | 2016 | 115 | 0.120 |
Why?
| | Epiphyses | 1 | 2015 | 26 | 0.120 |
Why?
| | Hyperlipidemias | 1 | 2016 | 124 | 0.120 |
Why?
| | Child, Preschool | 5 | 2016 | 11102 | 0.120 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 112 | 0.120 |
Why?
| | Antirheumatic Agents | 1 | 2018 | 291 | 0.120 |
Why?
| | Data Accuracy | 1 | 2015 | 65 | 0.120 |
Why?
| | Arthritis, Juvenile | 1 | 2015 | 54 | 0.110 |
Why?
| | Psoriasis | 1 | 2016 | 106 | 0.110 |
Why?
| | Polypharmacy | 1 | 2015 | 88 | 0.110 |
Why?
| | Adolescent | 7 | 2019 | 21435 | 0.110 |
Why?
| | Elbow Joint | 1 | 2015 | 75 | 0.110 |
Why?
| | Neoplasms | 2 | 2023 | 2691 | 0.110 |
Why?
| | Hedgehog Proteins | 1 | 2016 | 199 | 0.110 |
Why?
| | Young Adult | 7 | 2019 | 13203 | 0.110 |
Why?
| | Interferon-gamma | 1 | 2017 | 788 | 0.110 |
Why?
| | Prescription Drugs | 1 | 2015 | 114 | 0.110 |
Why?
| | Burnout, Professional | 1 | 2021 | 442 | 0.110 |
Why?
| | Dilatation | 1 | 2014 | 67 | 0.110 |
Why?
| | Cholesterol | 1 | 2016 | 400 | 0.110 |
Why?
| | Microbiota | 1 | 2022 | 759 | 0.110 |
Why?
| | Immunologic Factors | 1 | 2016 | 239 | 0.110 |
Why?
| | Anastomosis, Surgical | 1 | 2014 | 155 | 0.100 |
Why?
| | Streptococcal Infections | 1 | 2016 | 150 | 0.100 |
Why?
| | Virus Diseases | 1 | 2016 | 212 | 0.100 |
Why?
| | Radiation Injuries | 1 | 2014 | 147 | 0.100 |
Why?
| | Foreign Bodies | 1 | 2014 | 105 | 0.100 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 619 | 0.100 |
Why?
| | Disease Progression | 2 | 2021 | 2722 | 0.100 |
Why?
| | Early Detection of Cancer | 3 | 2022 | 432 | 0.100 |
Why?
| | Registries | 1 | 2021 | 2043 | 0.100 |
Why?
| | Reoperation | 1 | 2015 | 579 | 0.100 |
Why?
| | Physical Therapy Modalities | 1 | 2015 | 308 | 0.090 |
Why?
| | Primary Health Care | 2 | 2022 | 1769 | 0.090 |
Why?
| | Epidemiology | 1 | 2012 | 33 | 0.090 |
Why?
| | Diabetes Complications | 1 | 2013 | 225 | 0.090 |
Why?
| | Patient Readmission | 1 | 2017 | 701 | 0.090 |
Why?
| | Endoscopy | 1 | 2014 | 313 | 0.090 |
Why?
| | Tissue and Organ Procurement | 1 | 2015 | 319 | 0.090 |
Why?
| | Biomarkers | 2 | 2020 | 4092 | 0.090 |
Why?
| | Research Support as Topic | 1 | 2012 | 118 | 0.090 |
Why?
| | Age Distribution | 1 | 2012 | 397 | 0.090 |
Why?
| | Time Factors | 5 | 2021 | 6818 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2017 | 0.080 |
Why?
| | Physicians | 1 | 2019 | 924 | 0.080 |
Why?
| | Veterans | 1 | 2021 | 1476 | 0.080 |
Why?
| | Prospective Studies | 4 | 2024 | 7580 | 0.070 |
Why?
| | Medicare | 3 | 2021 | 777 | 0.070 |
Why?
| | Drug Prescriptions | 2 | 2024 | 257 | 0.070 |
Why?
| | Laparoscopy | 1 | 2012 | 445 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 2093 | 0.070 |
Why?
| | Neoplasm Staging | 2 | 2022 | 1359 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2021 | 506 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 887 | 0.060 |
Why?
| | Pennsylvania | 2 | 2017 | 131 | 0.060 |
Why?
| | Sex Factors | 2 | 2025 | 2046 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2016 | 2270 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1289 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1488 | 0.050 |
Why?
| | Regression Analysis | 2 | 2017 | 1010 | 0.050 |
Why?
| | Piperidines | 1 | 2024 | 206 | 0.050 |
Why?
| | Insurance Coverage | 1 | 2024 | 233 | 0.050 |
Why?
| | Gastrectomy | 1 | 2023 | 131 | 0.050 |
Why?
| | Replantation | 1 | 2021 | 31 | 0.040 |
Why?
| | Cost Savings | 1 | 2021 | 84 | 0.040 |
Why?
| | Granzymes | 1 | 2021 | 49 | 0.040 |
Why?
| | Review Literature as Topic | 1 | 2021 | 74 | 0.040 |
Why?
| | Documentation | 1 | 2023 | 199 | 0.040 |
Why?
| | Training Support | 1 | 2021 | 37 | 0.040 |
Why?
| | Fingers | 1 | 2021 | 104 | 0.040 |
Why?
| | Salaries and Fringe Benefits | 1 | 2021 | 56 | 0.040 |
Why?
| | Hand | 1 | 2021 | 159 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 319 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 183 | 0.040 |
Why?
| | Perception | 1 | 2022 | 366 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3287 | 0.040 |
Why?
| | SEER Program | 1 | 2020 | 220 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 182 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 347 | 0.040 |
Why?
| | Physician's Role | 1 | 2021 | 217 | 0.040 |
Why?
| | Medicine | 1 | 2021 | 126 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 517 | 0.040 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 321 | 0.040 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 90 | 0.040 |
Why?
| | Career Choice | 1 | 2021 | 227 | 0.040 |
Why?
| | Pharmacovigilance | 1 | 2018 | 23 | 0.040 |
Why?
| | Mathematical Concepts | 1 | 2018 | 32 | 0.040 |
Why?
| | Margins of Excision | 1 | 2017 | 42 | 0.030 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 238 | 0.030 |
Why?
| | Smoking | 1 | 2025 | 1597 | 0.030 |
Why?
| | Prednisone | 1 | 2018 | 216 | 0.030 |
Why?
| | Mercaptopurine | 1 | 2016 | 15 | 0.030 |
Why?
| | Hip Fractures | 1 | 2018 | 85 | 0.030 |
Why?
| | Etanercept | 1 | 2016 | 59 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2836 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1742 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1906 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1122 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 649 | 0.030 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 55 | 0.030 |
Why?
| | Decision Making | 1 | 2023 | 937 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 745 | 0.030 |
Why?
| | Cause of Death | 1 | 2018 | 424 | 0.030 |
Why?
| | Streptococcus pyogenes | 1 | 2016 | 43 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2021 | 620 | 0.030 |
Why?
| | Weight Loss | 1 | 2021 | 785 | 0.030 |
Why?
| | Methotrexate | 1 | 2016 | 251 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 424 | 0.030 |
Why?
| | Bias | 1 | 2016 | 224 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 498 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1752 | 0.030 |
Why?
| | Mental Recall | 1 | 2015 | 205 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 987 | 0.030 |
Why?
| | Medicaid | 1 | 2018 | 439 | 0.030 |
Why?
| | Anticoagulants | 1 | 2018 | 660 | 0.030 |
Why?
| | Waiting Lists | 1 | 2015 | 259 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1979 | 0.020 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 384 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2041 | 0.010 |
Why?
|
|
Scott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|